Peter W. PENG, Author at MediaMedic

Dr. Hui Wang: Second-line treatment choice for children with HIV infection

By Peter W. PENG 2023.10.12

Currently, the choice of second-line antiretroviral therapy (ART) for children infected with HIV is extremely limited. At the12th International AIDS Society HIV Science Conference (IAS 2023), researchers announced the results of a significant clinical study, the CHAPAS-4 ( Abstract No. OALBB0503), focusing on the long-term treatment outcomes of second-line therapy in children with HIV infections. We specially invited Dr. Hui Wang from the Affiliated Second Hospital of Southern University of Science and Technology, China, to provide a brilliant review of this research.

Dr. YunHe: The Impact of Rapid ART Initiation on HIV Outcomes

By Peter W. PENG 2023.10.12

The concept of rapid initiation of antiretroviral therapy (ART) has been proposed for nearly 10 years, and many studies have confirmed the long-term benefits of rapid ART initiation. At the 12th International AIDS Society HIV Science Conference (IAS 2023), Thai scholar Sirinya Teeraananchai reported a study on the impact of rapid ART initiation on the health outcomes of People Living with HIV (PLWH). Dr.Yun He from the Third People's Hospital of Shenzhen, China, was specially invited to comment on the study as follows.

Dr. WeiCao: Focus on Managing HIV Complications, Further Improving Patient Survival

By Peter W. PENG 2023.10.12

The 12th International AIDS Society Conference on HIV Science (IAS 2023) was held from July 23-26, 2023, in Brisbane, Australia. As the largest open scientific conference in the global field of HIV/AIDS, it attracted the participation of experts, medical professionals, community organizations, and healthcare companies worldwide. Dr. Wei Cao from Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, was invited to attend the conference and was interviewed on-site by Infectious Disease Frontier. We have invited Dr. Cao to share the latest developments emerging from this conference and hot topics related to HIV/AIDS treatment.

Dr.HongzhouLu: NAD Management is Key for HIV Patients, Not Just Changing Medication

By Peter W. PENG 2023.10.12

The use of highly active antiretroviral therapy (HAART) has led to effective virological control in HIV-infected individuals, significantly reducing mortality rates and transforming AIDS into a treatable and manageable chronic disease. Today, one of the main clinical challenges is how to choose more "efficient and less toxic" treatment options to improve patients' quality of life. At the 12th International AIDS Society HIV Science Conference (IAS 2023) held recently, the first randomized controlled trial on switching to integrase strand transfer inhibitor (INSTI)-based therapy to control weight gain was reported. Infectious Disease Frontier invited Dr. Hongzhou Lu from Shenzhen Third People's Hospital, China, to interpret this trial and share insights into the current and future management of non-AIDS defining diseases (NAD) in HIV-infected individuals.

Challenges in HIV Management: Enhancing the Quality of Life for Elderly PLWH, Policy Interventions are Imperative

By Peter W. PENG 2023.10.12

From July 23-26, 2023, the 12th International AIDS Society HIV Science Conference (IAS 2023) was held in Brisbane, Australia. In recent years, with the continuous advancement of modern antiretroviral therapy (ART), the life expectancy of people living with HIV (PLWH) has significantly improved. However, the accompanying aging issue of PLWH is becoming increasingly prominent, posing unprecedented challenges to HIV management. The quality of life and living conditions of elderly PLWH have become hot topics of discussion at this conference.

Dr. WeipingCai: Long-Acting Antiretroviral Drugs Usher in a New Chapter in AIDS Care

By Peter W. PENG 2023.10.12

AIDS remains one of the most significant public health issues worldwide, with around 38 million people living with HIV (PLWH). In recent years, with the continuous advancement of antiretroviral therapy (ART), AIDS has gradually transformed into a manageable chronic disease. However, PLWH still face challenges like poor drug adherence and increased risk of resistance.

Interview with Dr. Andreas Rimner: The Role of Radiotherapy in the Treatment of Stage III Thymoma

By Peter W. PENG 2023.10.12

Thymoma is one of the most common primary tumors in the anterior mediastinum, representing a group of diseases originating from different thymic epithelial cells, characterized by unique clinical and pathological features, often accompanied by various paraneoplastic syndromes. During the "Multidisciplinary Oncology Committee" session held at the 2023 European Lung Cancer Congress (ELCC), several experts discussed the treatment strategies for Stage III thymoma based on a case study. Dr. Andreas Rimner from Memorial Sloan Kettering Cancer Center presented on "The Timing of Radiotherapy in the Treatment of Stage III Thymoma." In an interview with Oncology Frontier, Andreas Rimner shares insights into the role of radiotherapy in the treatment of Stage III thymoma.

Interview with Dr. Martin Reck at ELCC 2023

By Peter W. PENG 2023.10.12

The 2023 European Lung Cancer Congress (ELCC) recently concluded in Copenhagen. In an interview with Oncology Frontier, 2023 ELCC Scientific Co-Chairs Professor Martin Reck reviewed the most significant oral presentations of the conference and shared insights on the selection of first-line immunotherapy regimens.

Dr. P. Garrido Lopez Interprets Latest Data from CHRYSALIS

By Peter W. PENG 2023.10.12

On the first day of the 2023 European Lung Cancer Congress (ELCC), during the oral presentation session, Dr. P. Garrido Lopez from Ramón y Cajal University Hospital in Madrid, Spain, presented the long-term efficacy, safety, and predictive factors of amivantamab in the treatment of platinum-treated EGFR exon 20 insertion (EGFR ex20ins) mutant advanced non-small cell lung cancer (NSCLC) patients in the CHRYSALIS trial (Abstract No. 3O). In an interview with "Tumor Insight," P. Garrido Lopez further elucidated the results of the CHRYSALIS trial and its clinical significance.

Interview with Dr. Luis Paz-Ares: PD-L1 High Expression in Advanced NSCLC, IO Monotherapy vs. IO + Chemotherapy

By Peter W. PENG 2023.10.12

At the recently concluded 2023 European Lung Cancer Congress (ELCC), Professor Luis Paz-Ares from Madrid University Hospital in Spain presented results from a Phase II trial called CARMEN-LC05 (NCT04524689). The results showed that the antibody-drug conjugate (ADC) targeting CEACAM5, Tusamitamab ravtansineA, in combination with or without pembrolizumab, and chemotherapy, produced responses in CEACAM5-positive non-squamous non-small cell lung cancer (NSCLC) patients in the first-line treatment, and it was well-tolerated.